Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
45.90
-0.96 (-2.05%)
Aug 28, 2026, 10:17 AM EDT - Market open
Rigel Pharmaceuticals Revenue
Rigel Pharmaceuticals had revenue of $78.70M in the quarter ending June 30, 2026, a decrease of -22.60%. This brings the company's revenue in the last twelve months to $276.79M, up 3.31% year-over-year. In the year 2025, Rigel Pharmaceuticals had annual revenue of $294.28M with 64.15% growth.
Revenue (ttm)
$276.79M
Revenue Growth
+3.31%
P/S Ratio
3.16
Revenue / Employee
$1,590,718
Employees
174
Market Cap
857.41M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 294.28M | 115.00M | 64.15% |
| Dec 31, 2024 | 179.28M | 62.40M | 53.38% |
| Dec 31, 2023 | 116.88M | -3.36M | -2.79% |
| Dec 31, 2022 | 120.24M | -28.99M | -19.43% |
| Dec 31, 2021 | 149.24M | 40.62M | 37.39% |
| Dec 31, 2020 | 108.62M | 49.33M | 83.21% |
| Dec 31, 2019 | 59.29M | 14.78M | 33.20% |
| Dec 31, 2018 | 44.51M | 40.03M | 892.62% |
| Dec 31, 2017 | 4.48M | -15.90M | -78.00% |
| Dec 31, 2016 | 20.38M | -8.51M | -29.46% |
| Dec 31, 2015 | 28.90M | 20.65M | 250.24% |
| Dec 31, 2014 | 8.25M | 1.10M | 15.38% |
| Dec 31, 2013 | 7.15M | 4.90M | 217.78% |
| Dec 31, 2012 | 2.25M | -2.50M | -52.63% |
| Dec 31, 2011 | 4.75M | -120.25M | -96.20% |
| Dec 31, 2010 | 125.00M | 124.25M | 16,566.67% |
| Dec 31, 2009 | 750.00K | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | 12.60M | -20.87M | -62.36% |
| Dec 31, 2006 | 33.47M | 16.95M | 102.55% |
| Dec 31, 2005 | 16.53M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 366.48M |
| Theravance Biopharma | 104.31M |
| 4D Molecular Therapeutics | 92.01M |
| Aclaris Therapeutics | 8.22M |
| DBV Technologies | 5.04M |
| Attovia Therapeutics | 1.35M |
| Silence Therapeutics | 615.00K |
RIGL News
- 11 days ago - Rigel Pharmaceuticals price target raised to $49 from $40 at Piper Sandler - TheFly
- 11 days ago - Rigel Pharmaceuticals’ Veppanu available for metastatic breast cancer - TheFly
- 12 days ago - Rigel Pharmaceuticals price target raised to $85 from $57 at H.C. Wainwright - TheFly
- 15 days ago - Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer - PRNewsWire
- 22 days ago - Rigel Pharmaceuticals price target raised to $83 from $81 at Citi - TheFly
- 23 days ago - Rigel Pharmaceuticals raises FY26 revenue view to $285M-$295M from $275M-$290M - TheFly
- 23 days ago - Rigel Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 23 days ago - Rigel Pharmaceuticals Earnings release: Q2 2026 - Filings